Kura Oncology vs Syndax Pharmaceuticals
KURA and SNDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How KURA and SNDX compare
Syndax Pharmaceuticals is the larger company, worth 1.2 times as much as Kura Oncology ($764M against $653M).
Syndax Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −72.3% compared with −369% at Kura Oncology.
Syndax Pharmaceuticals scores higher on the StockData Score (3 against 1 for Kura Oncology), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | KURA | SNDX |
|---|---|---|
| Size and price | ||
| Market cap | $653M | $764M |
| Share price | $7.34 | $8.56 |
| Change, 1 year | −32.4% | −50.2% |
| Change, 5 years | −47.6% | −48.1% |
| Beta (5Y) | 1.27 | 1.08 |
| Employees | 260 | 298 |
| StockData Score | ||
| Total score | 1 | 3 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.2× | 2.6× (better) |
| P/B | 36.4× | – |
| FCF yield | −13.6% | – |
| Growth | ||
| Revenue growth (TTM) | – | 160% |
| Revenue growth, 5Y average | – | 158% |
| Profitability | ||
| Operating margin | −394% | −61.7% (better) |
| Net margin | −369% | −72.3% (better) |
| FCF margin | −112% | – |
| Return on equity | −225% (better) | −426% |
| Financial health | ||
| Debt / equity | 0.55 | – |
| Interest coverage | −227.1× (better) | −44660.0× |
| Current ratio | 3.60 | 4.69 (better) |
| Altman Z-score | −3.58 | −2.34 (better) |
| Piotroski F-score | 1 | 3 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 98.0% | 121% |
| Held by insiders | 2.7% | 1.8% |
| Insider net buying, 12 months | $2.0M (better) | −$2.9M |
| Short interest, % of float | 14.6% | 21.6% |
Go deeper
- KURA stock overview
- KURA income statement
- KURA valuation and score
- SNDX stock overview
- SNDX income statement
- SNDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.